Cargando…

Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy

OBJECTIVE: This study was to determine whether peripheral blood biomarkers including neutrophil‑lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) could predict early response to cetuximab; moreover, the prognostic ability of those biomarkers on pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jinling, Ma, Tao, Xi, Wenqi, Yang, Chen, Wu, Junwei, Zhou, Chenfei, Wang, Nan, Zhu, Zhenggang, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767765/
https://www.ncbi.nlm.nih.gov/pubmed/31576170
http://dx.doi.org/10.2147/CMAR.S211089
_version_ 1783454990666301440
author Jiang, Jinling
Ma, Tao
Xi, Wenqi
Yang, Chen
Wu, Junwei
Zhou, Chenfei
Wang, Nan
Zhu, Zhenggang
Zhang, Jun
author_facet Jiang, Jinling
Ma, Tao
Xi, Wenqi
Yang, Chen
Wu, Junwei
Zhou, Chenfei
Wang, Nan
Zhu, Zhenggang
Zhang, Jun
author_sort Jiang, Jinling
collection PubMed
description OBJECTIVE: This study was to determine whether peripheral blood biomarkers including neutrophil‑lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) could predict early response to cetuximab; moreover, the prognostic ability of those biomarkers on progression free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) patients with wild-type (WT) RAS was also investigated. METHODS: mCRC patients with WT RAS treated with cetuximab plus chemotherapy were retrospectively analyzed, and early response was evaluated according to RECIST 1.1 after three or four treatment cycles. In prior to chemotherapy, hematologic data and clinic-pathological parameters were collected. The associations between pre-treatment inflammatory biomarkers and early response, and the prognostic value of those biomarkers were analyzed. A total of 102 patients were enrolled and divided into low or high NLR, PLR, and SII groups, respectively. RESULTS: The early response rate was significantly higher in the low NLR (p<0.001), low PLR (p=0.045), and low SII (p=0.011), respectively. In multivariate analyses, primary tumor resection (hazard ratio (HR) 0.411, p<0.001), carcino-embryonic antigen ≤5 ng/mL (HR 0.406, p<0.001), early treatment response (HR 0.322, p<0.001), and low NLR (HR 0.665, p=0.031) were independent factors of longer PFS. Primary tumor resection (HR 0.488, p=0.003) and early response (HR 0.392, p<0.001) were independent factors of longer OS. Further analysis showed that patients with early response, even in the high groups, can achieve better PFS and OS than non-responders. CONCLUSION: Pre-treatment inflammatory biomarkers, especially NLR were predictors of benefit from cetuximab-combined therapy in mCRC patients. They were also predictors of significantly longer PFS and OS of early responders compared to non-responders.
format Online
Article
Text
id pubmed-6767765
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67677652019-10-01 Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy Jiang, Jinling Ma, Tao Xi, Wenqi Yang, Chen Wu, Junwei Zhou, Chenfei Wang, Nan Zhu, Zhenggang Zhang, Jun Cancer Manag Res Original Research OBJECTIVE: This study was to determine whether peripheral blood biomarkers including neutrophil‑lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) could predict early response to cetuximab; moreover, the prognostic ability of those biomarkers on progression free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) patients with wild-type (WT) RAS was also investigated. METHODS: mCRC patients with WT RAS treated with cetuximab plus chemotherapy were retrospectively analyzed, and early response was evaluated according to RECIST 1.1 after three or four treatment cycles. In prior to chemotherapy, hematologic data and clinic-pathological parameters were collected. The associations between pre-treatment inflammatory biomarkers and early response, and the prognostic value of those biomarkers were analyzed. A total of 102 patients were enrolled and divided into low or high NLR, PLR, and SII groups, respectively. RESULTS: The early response rate was significantly higher in the low NLR (p<0.001), low PLR (p=0.045), and low SII (p=0.011), respectively. In multivariate analyses, primary tumor resection (hazard ratio (HR) 0.411, p<0.001), carcino-embryonic antigen ≤5 ng/mL (HR 0.406, p<0.001), early treatment response (HR 0.322, p<0.001), and low NLR (HR 0.665, p=0.031) were independent factors of longer PFS. Primary tumor resection (HR 0.488, p=0.003) and early response (HR 0.392, p<0.001) were independent factors of longer OS. Further analysis showed that patients with early response, even in the high groups, can achieve better PFS and OS than non-responders. CONCLUSION: Pre-treatment inflammatory biomarkers, especially NLR were predictors of benefit from cetuximab-combined therapy in mCRC patients. They were also predictors of significantly longer PFS and OS of early responders compared to non-responders. Dove 2019-09-24 /pmc/articles/PMC6767765/ /pubmed/31576170 http://dx.doi.org/10.2147/CMAR.S211089 Text en © 2019 Jiang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jiang, Jinling
Ma, Tao
Xi, Wenqi
Yang, Chen
Wu, Junwei
Zhou, Chenfei
Wang, Nan
Zhu, Zhenggang
Zhang, Jun
Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title_full Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title_fullStr Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title_full_unstemmed Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title_short Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
title_sort pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767765/
https://www.ncbi.nlm.nih.gov/pubmed/31576170
http://dx.doi.org/10.2147/CMAR.S211089
work_keys_str_mv AT jiangjinling pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT matao pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT xiwenqi pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT yangchen pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT wujunwei pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT zhouchenfei pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT wangnan pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT zhuzhenggang pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy
AT zhangjun pretreatmentinflammatorybiomarkerspredictearlytreatmentresponseandfavorablesurvivalinpatientswithmetastaticcolorectalcancerwhounderwentfirstlinecetuximabpluschemotherapy